KING OF PRUSSIA, Pa. & NEW YORK--(BUSINESS WIRE)-- Trevena Inc., (Trevena) a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptors (GPCR) ...

What: Shares of the clinical-stage biotech Trevena fell by as much as 18% today after the company announced that its experimental drug, TRV027, failed to meet either its primary or secondary endpoints ...

What: Trevena (TRVN +0.00%) is up more than 10% at 1:15 p.m. ET after the company announced that its pain medication oliceridine was given Breakthrough Therapy designation by the Food and Drug ...

<0> TRV027 improves hemodynamics and is well-tolerated in patients with stable advanced heart failure, supporting advancement into a Phase 2b study in ADHF </0> Trevena, Inc.Alastair Southwell, ...

On Thursday, tiny King of Prussia, Pennsylvania-based biotech Trevena (TRVN) released the data from an Imperial College London trial involving 30 patients enrolled in the proof-of-concept study of its ...

Trevena, Inc., the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, announced that results from a study into the cardioprotective actions of its Angiotensin II Type 1 ...

Shares of drug maker Trevena (TRVN) are up by 112% in 2020. Behind the rally lies the FDA’s approval of Olinvyk (oliceridine), the company’s opioid agonist. The treatment has been given the go ahead ...